None listed
Conditions
Interventions
Case series :taking imrecoxib
Sponsors
Xinxiang central hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. aged 18 to 75 years, men and women; 2. in the American rheumatism association (ACR) standard primary osteoarthritis of the knee joint, symptoms for at least 3 months (can be diagnosed when screening). According to the function of ACR classification, joint function level I, II or III; 3. understand and are willing to sign a consent form, following the research plan.
Exclusion criteria
Exclusion criteria: 1. the following subjects: cardiovascular events happened - 6 months before screening, myocardial infarction or coronary bypass surgery or traumatic coronary artery recanalization or stroke of the subjects; - unstable angina pectoris (unstable angina pectoris: an increased frequency of angina pectoris attack, a period of 6 months before screening new angina, resting angina pectoris and mild exercise of angina pectoris, including decubitus angina no stimulation (state), night attack of angina pectoris and variant angina pectoris); - after the rest or mild exercise have symptoms of congestive heart failure (NYHA class ? - ? and ejection fraction of 35% or less) of the subjects 2. poor control of blood pressure, blood pressure (SBP > 180 MMHG and/or DBP > 100 MMHG) of the subjects; 3. after the application of non-steroidal anti-inflammatory drugs, subjects with a history of gastrointestinal bleeding or perforation; 4. 30 days before the screening with active peptic ulcer hemorrhage of the subjects, or ever had recurrent ulcer bleeding of the subjects; 5. Taking aspirin > 150 mg/d of the subjects; 6. known to sulfa, cox-2 kind drug allergy, taking aspirin or other non-steroidal anti-inflammatory drugs (nsaids) induced asthma, urticaria, or allergic reaction after the subjects 7. urine HCG test results before test positive for women; During the test did not take effective contraceptive measures; 8. within three days before the screening is still accept other non-steroidal anti-inflammatory drugs (NSAIDs) treatment of the subjects; 9. screening the AST and ALT > upper limit of normal for 2 times, 1.5 times or BUN > normal upper limit of the subjects; 10. the researchers think that has any unfavorable factors of the subjects to participate in this test.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| blood routine examination;blood biochemical examination;Musculoskeletal ultrasound; | — |
Countries
China
Contacts
Public ContactGao Xiao
Outcome results
None listed